PNEUMOFOCUS

BULLETIN OF GAVI'S PNEUMOADIP AT JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH
PNEUMO ADIP: PNEUMOCOCCAL VACCINES ACCELERATED DEVELOPMENT AND INTRODUCTION PLAN


Volume 1, No. 7 July, 2004
EXECUTIVE DIRECTOR'S NOTE
This month's issue is one part reminder, one part newspaper, and one part advertisement. It's a reminder to check our website for information on our Small Grants program and our solicitation for potential vaccine evaluation sites in Asia. In this issue Heather Parsons reports on the recent experience with pneumococcal vaccine introduction in Australia which highlights the political side of this process. Lastly, we're advertising to make people aware of the many useful disease burden tools available on the WHO website. Lastly, I want to recognize our Research Project Coordinator, Farzana Muhib, for her outstanding work in developing and organizing our Small Grants process. The first round of Small Grants closed on June 15th and we're pleased to have received 15 applications from 9 countries. The consistency and quality of these applications are reflection of the investigators, and of Farzana's work to develop the forms and applications materials.



Orin Levine
Executive Director
FUNDING INFORMATION
Small Grants Program
Our next small grants deadline is October 15th. Please visit us online at www.preventpneumo.org for more information and application procedures.

Solicitation for Potential Asian Field Sites
Our website provides information about PneumoADIP’s request for letters of interest for potential sites in the Asian and Pacific regions to conduct large scale vaccine evaluations. Brief (4 pages) letters of interest are due September 1st, 2004.

THE POLITICS OF VACCINATION
Nearly two years after medical experts made an evidence-based case to the Australian government arguing for universal childhood immunization with pneumococcal conjugate vaccine, the country’s children will begin receiving it, Minister of Health Tony Abbott announced June 11. All children born since January 1, 2003 will receive a free, three dose regimen of the vaccine. The government has estimated that the program, which will vaccinate all babies born in the country through the end of 2006, will cost 178 million Australian dollars.

But lead officials of the opposition Labor Party say the program is still too small and has come too late, a charge backed by national groups of parents and doctors, and that the conservative government of Prime Minister John Howard has only funded the vaccinations grudgingly, after months of sustained public pressure.

Some medical professionals had been pushing for pneumococcal vaccination since Prevenar was licensed in 2000. Doctors serving the largely impoverished Aboriginal community, where pneumococcal disease is particularly frequent and serious and where parents frequently cannot afford the vaccines, argued for a government funded solution and won. Since 2001, the Australian government has provided freed vaccinations for Aboriginal children and other ‘high-risk’ children. But those pushing for universal immunization of all Australian children had little luck convincing either the government or the opposition Labor Party that funding for this new vaccine ought to be a political priority.

But the public opinion environment changed last fall, when Wyeth introduced its vaccine to prevent meningococcal serogroup C meningitis, and millions of middle class parents persuaded the government to provide it. That fight raised the public profile of meningitis, and the parents´ groups, now organized, turned their attention to the pneumococcal vaccine, which would prevent the most deadly cases of meningitis. Labor went one step further, calling upon Howard´s government to provide free childhood vaccines for pneumococcus, varicella, and polio.

The government initially argued that these vaccines would be too expensive, but after continued public pressure the Ministry of Health negotiated a deal with Wyeth, which lowered the cost of the vaccines in exchange for a guaranteed bulk order sufficient to treat every child born in Australia for the next two years.

Though they cheer the program’s funding, the case has taught public health professionals that evidence alone may not be sufficient to assure vaccine introduction. Change in government policy is likely to come only as a result of vast political pressure. ¨For me it’s been a revelation,´ said Dr. Kim Mulholland of the Department of Paediatrics at the Royal Children’s Hospital in Victoria. ¨I thought public health decisions weren’t made this way anymore.¨
AUGUST IS MENINGITIS AWARENESS AND PREVENTION MONTH

Recognizing the need for greater knowledge of the dangers of meningitis, the Meningitis Foundation of America has declared August 2004 the first annual Meningitis Awareness and Prevention Month. Activities will focus on increasing the awareness of the signs and symptoms of meningitis in the US, and encouraging the use of the several life saving vaccines available to protect against this deadly disease. For more information please visit www.musa.org

A WEALTH OF RESOURCES ON WHO WEBSITE

The World Health Organization has recently made its valuable review of global Hib meningitis available on its Ïmmunizations, Vaccines and Biologicals¨ website at www.who.int/vaccines-documents/doxgen/h3doxlist.htm. For anyone who hasn’t seen it this is an exhaustive analysis of the relevant global data on Hib meningitis, with summary graphs and detailed tables.

In addition the website is a rich resource for protocols, reviews and other documents that WHO has published that are relevant to establishing the burden of Hib and pneumococcal disease and the value of vaccination. Below is a list of highlights from the website. Please click on the link above to find these articles.

Disease burden tools available on the WHO Website:

Haemophilus influenzae type b (Hib) meningitis in the pre-vaccine era:
a global review of incidence, age distributions, and case-fatality rates
(WHO/V&B/02.18)

Estimating the potential cost-effectiveness of using Haemophilus influenzae type b (Hib) vaccine. Field test version 1 (WHO/V&B/01.36)

Expert review of a tool for rapidly assessing Haemophilus influenzae type b (Hib) disease burden, Geneva, 19-20 October 2000 (WHO/V&B/01.25)

Generic protocol for population-based surveillance of haemophilus influenzae type B (WHO/VRD/GEN/95.05)

Guidelines for estimating costs of introducing new vaccines into the national immunization system (WHO/V&B/02.11)

Haemophilus influenzae type b immunization (fact sheet) (WHO/V&B/01.29)

Introduction of Haemophilus influenzae type b (Hib) vaccine into immunization programmes. Management guidelines, including information for health workers and parents (WHO/V&B/00.05)

Priorities for pneumococcal and Haemophilus influenzae type b (Hib) vaccine development and introduction. Geneva, 9-12 February 1999. Report of a meeting (WHO/V&B/01.14)

WHO-recommended standards for surveillance of selected vaccine-preventable diseases (WHO/V&B/03.01)

Working group for economic evaluation of pneumococcal and Haemphophilus influenzae type b vaccines. Report of the first meeting, Geneva, 19-20 June 2000 (WHO/V&B/01.20)

And for laboratory procedures try this WHO website:

Manual for the laboratory identification and antimicrobial susceptibility testing of bacterial pathogens of public health concern in the developing world WHO/CDS/CSR/RMD/2003.6

http://www.who.int/csr/resources/publications/drugresist/WHO_CDS_CSR_RMD_2003_6/en/